Some on-the-surface uneventful news this morning from NNVC, but I am posting it here because of the concise summary of the underlying science behind the company's patents, a concept that each and every one of you shareholders should understand, so the next time you are tempted to bail out early, you pause and consider the implications of not being on board for the entire ride.
NanoViricides Announces Trademark Registration for "Nanoviricides"
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the mark “nanoviricides” has now become a registered trademark under the US Patents and Trademarks Office (USPTO). The mark was entered into the “principal register” of trademarks at the USPTO on April 20, 2010.
The mark “nanoviricides” consists of standard characters without claim to any particular font, style, size, or color. It is protected in the corresponding plural and singular forms as well as any capitalizations.
The Company created the novel word “nanoviricide®” in 2005. The Company defined “nanoviricide” to describe a specific type of antiviral nanomaterial that is designed to be capable of binding to, encapsulating, and potentially destroying virus particles. Nanoviricides are based on the TheraCour® polymeric micelle technology.
A nanoviricide is created by chemically attaching a “ligand” to a base TheraCour nanomicelle. The ligand is a special chemical entity that is designed to bind to a virus particle. The specificity of a nanoviricide is expected to be determined by the specificity of the ligand.
Viruses continuously change by a number of mechanisms such as mutations, recombinations, or re-assortments. This is why influenza vaccines and antibodies do not always work well against novel strains of influenza. This is also why attempts to develop “universal” vaccines against a number of different viruses such as HIV, Influenza, Dengue, and Ebola have met with limited successes.
It is generally accepted that, in spite of extensive changes in the virus, a given virus continues to bind to the same cell surface receptor(s) in the same fashion. The Company believes that it is possible to design ligands which mimic such invariant binding signature of a given virus. Using such biomimetic ligands, the Company believes that it is possible to create a nanoviricide that will remain active against a given type of virus, in spite of the changes the virus undergoes. The Company believes that a nanoviricide so designed would “fool” the virus into thinking that the virus is binding to and entering a host cell, while in fact it would be binding to and becoming entrapped inside a nanoviricide micelle. The Company believes that some viruses may be dismantled or destroyed upon interaction with a nanoviricide designed against them. Thus the Company believes that there is a strong likelihood of developing nanoviricides from which a given virus could not escape, in spite of mutations.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
